Therefore, we conducted a prospective multicenter study with the goal of determining the detection methods and detection periods of EGFR mutation and ALK rearrangement, the EGFR mutation rate, ALK rearrangement rate, and first‐line targeted therapy rate in patients with NSCLC harboring EGFR mutations or ALK rearrangement in northern China. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.